Page 102 - Quantitative Imaging of Small Tumours with Positron Emission Tomography

References 1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308. 2. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160. 3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. 4. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433. 5. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197. 4 6. Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-1418. 7. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha- dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373. 8. Beattie BJ, Smith-Jones PM, Jhanwar YS, et al. Pharmacokinetic assessment of the uptake of 16beta- 18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183-192. 9. Fox JJ, Gavane SC, Blanc-Autran E, et al. Positron Emission Tomography/Computed Tomography- Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018;4:217-224. 10. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437-1446. 11. Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31:3525-3530. 12. Vargas HA, Kramer GM, Scott AM, et al. Reproducibility and Repeatability of Semiquantitative (18) F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med. 2018;59:1516-1523. 13. Hausmann D, Dinter DJ, Sadick M, Brade J, Schoenberg SO, Busing K. The impact of acquisition time on image quality in whole-body 18F-FDG PET/CT for cancer staging. J Nucl Med Technol. 2012;40:255- 258. 14. Kadrmas DJ, Oktay MB, Casey ME, Hamill JJ. Effect of Scan Time on Oncologic Lesion Detection in Whole-Body PET. IEEE Trans Nucl Sci. 2012;59:1940-1947. 15. Kaalep A, Sera T, Oyen W, et al. EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging. 2018;45:412-422. 16. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354. 17. Rahmim A, Qi JY, Sossi V. Resolution modeling in PET imaging: Theory, practice, benefits, and pitfalls. Medical Physics. 2013;40. 18. Munk OL, Tolbod LP, Hansen SB, Bogsrud TV. Point-spread function reconstructed PET images of sub-centimeter lesions are not quantitative. EJNMMI Phys. 2017;4:5. 19. Kramer GM, Yaqub M, Vargas HA, et al. Assessment of simplified methods for quantification of (18) F-FDHT uptake in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2019. 20. Narayanan M, Perkins A. Resolution recovery in the Ingenuity TF PET/CT [White Paper]. Retrieved January 23, 2019 from Philips Healthcare: http://clinical.netforum.healthcare.philips.com/us_en/ Explore/White-Papers/PetCT/Resolution-recovery-in-the-Ingenuity-TF-PET-CT. 21. Kramer GM, Frings V, Heijtel D, et al. Parametric Method Performance for Dynamic 3'-Deoxy-3'-(18) F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy. J Nucl Med. 2017;58:920-925. [18F]FDHT PET repeatability 101